<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686386</url>
  </required_header>
  <id_info>
    <org_study_id>RV-MM-GIMEMA/GISL430</org_study_id>
    <secondary_id>2010-018336-40</secondary_id>
    <nct_id>NCT01686386</nct_id>
  </id_info>
  <brief_title>Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma</brief_title>
  <official_title>A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open Label, Phase I/II, multicenter study. In the first phase it defines the
      maximum tolerated dose (MTD) of Bendamustine (B) given in combination with Lenalidomide (L)
      and low-dose Dexamethasone (d) and in the second phase it evaluates the antitumour activity
      of Bendamustine, Lenalidomide and Low-dose Dexamethasone (BdL) given in combination, in
      relapsed multiple myeloma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma is a B-cell malignancy resulting from the monoclonal proliferation of plasma
      cells within the bone marrow. According to the American Cancer Society, 14,600 new cases of
      multiple myeloma will be diagnosed in 2002, and these will account for approximately 1% of
      all new cancer cases. Multiple myeloma will contribute to 2% of all cancer deaths this year;
      an estimated 10,800 deaths will occur overall. The disease is more prevalent in men and is
      twice as common in African-Americans as in Caucasians. Multiple myeloma is commonly thought
      of as a disease of older patients; the median age at diagnosis is 68 years, and the incidence
      increases more than 4%/year in those older than 85 years. The median survival with standard
      treatment is only 3 years.

      Therapeutic options for patients with multiple myeloma (MM) are rapidly changing. The
      emergence of two highly active novel agents, bortezomib and lenalidomide, have dramatically
      changed the landscape of treatment options and have improved outcomes for many patients.
      Combinations of conventional agents with novel agents have also demonstrated significant
      efficacy for patients with newly diagnosed and relapsed myeloma. Among the conventional
      agents that are being explored is the bifunctional alkylator agent bendamustine, which has
      demonstrated single-agent activity and activity with novel agents.

      Lenalidomide is a new immunomodulating agent effective in multiple myeloma, especially when
      associated with dexamethasone or melphalan and prednisone. The role of lenalidomide in the
      treatment of relapsed/refractory patients with MM has been established and current research
      is focused on the combination of lenalidomide with chemotherapy to further improve results.

      Bendamustine is a bi-functional alkylating agent with a purine- like benzimidazole ring that
      has been administered successfully to patients with MM. In vitro studies showed that
      bendamustine possesses a unique profile of activity, which was clearly divergent from other
      common nitrogen mustard drugs. Bendamustine and prednisone in newly diagnosed MM patients
      results in superior complete response rate, prolonged time to treatment failure and improved
      quality of life compared to treatment with melphalan and prednisone. The role of
      bendamustine, thalidomide and prednisolone (BPT) in patients with relapsed or refractory
      diseases stage II/III has been investigated by the East German Study group of Hematology and
      Oncology (OSHO). The response rate was higher than 80%.

      Despite the impressive efficacy of the lenalidomide/dexamethasone in relapsed MM, treated
      patients will eventually relapse (median Time to Progression (TTP) is expected to be nearly a
      year according the results of the two phase III randomized studies). Combination with an
      effective novel agent as bendamustine could further increase both the response rate and the
      TTP of lenalidomide/dexamethasone and induce durable responses in relapsed or refractory MM
      patients. The identification of an appropriate lenalidomide dose to be adopted in combination
      with bendamustine and dexamethasone and the generation of exploratory data on the efficacy of
      this novel combination appears to be important in terms of future development of even more
      effective treatments of MM.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I:Determination of Maximum Tolerated Dose</measure>
    <time_frame>up to 28 days during first cycle</time_frame>
    <description>In the first phase of the study, the dose of Bendamustine and Lenalidomide given with will be gradually escalated to reach the Maximum Tolerated Dose. The Maximum Tolerated Dose of Bendamustine and Lenalidomide will be evaluated during the first course (cycle 1) of Bendamustine Dexamethasone Lenalidomide (BdL) administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I:Determination of occurrence rate of AE/SAEs</measure>
    <time_frame>up to 28 day (during the first cycle 1of BdL administered)</time_frame>
    <description>To assess the Safety and Toxicity of the Bendamustine,Dexamethasone and Lenalidomide (BdL) regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall Response Rate (ORR)</measure>
    <time_frame>An avarage of 6 months (after 6 cycles of therapy)</time_frame>
    <description>To assess the antitumour activity of the BdL regimen, in term of Complete response, Partial response and Stable disease, according to the best schedule identified during Phase I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Assessment of the preliminary antineoplastic properties of the BdL</measure>
    <time_frame>after an avarage of 6 months</time_frame>
    <description>To explore the preliminary antitumor activity of drug combination in patients with relapsed MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: AE/SAEs</measure>
    <time_frame>Every 28 days (during all cycles)</time_frame>
    <description>To define the safety profile of the treatment assessing the occurrence rate and the severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II:Determination of the response rates</measure>
    <time_frame>Assessed after 6 months</time_frame>
    <description>To assess Partial Response and Complete Response rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II:Time to Event parameters</measure>
    <time_frame>avarage 6 months</time_frame>
    <description>To evaluate the efficacy of the BdL regimen in patients with relapsed MM, in terms of Progression-Free Survival, Time to Progression, Time to Response, Duration of Response ,Overall Survival(PFS, TTP, TTR, DR, OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose escalation benda lena dexa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.
Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.</description>
    <arm_group_label>Dose escalation benda lena dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.</description>
    <arm_group_label>Dose escalation benda lena dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Phase I and Phase II Dexamethasone fixed dose 40 mg/die</description>
    <arm_group_label>Dose escalation benda lena dexa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary written informed consent

          -  Men and women age ≥ 18 years

          -  Female subjects are either post-menopausal or surgically sterilized or willing to use
             2 simultaneous methods of contraception

          -  Male patients must agree to use a latex condom during sexual contact with females of
             childbearing potential throughout the study and for at least 28 days following
             discontinuation of lenalidomide;

          -  Confirmed diagnosis of Multiple Myeloma with measurable disease .Patients with
             evidence of relapsed disease after more than 1 and equal but not more than 3 prior
             lines of therapy.

          -  ECOG Performance Status 0 - 2

          -  Required baseline haematology and chemistry parameters

        Exclusion Criteria:

          -  Myocardial infarction within 6 months prior to enrollment or has NYHA class III or IV
             heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

          -  Female subjects either pregnant or breast-feeding (negative serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test result)

          -  Patients have received other investigational drugs with 14 days before enrollment.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Any of the following laboratory abnormalities:

        Absolute neutrophil count (ANC) &lt;1,000 /μl (1x109 /L) Untransfused platelet count &lt;
        50,0000cell/μl (50x109 /L) Serum SGOT/AST or SGPT/ALT &gt; 2.0 upper limit of normal (ULN)
        Total bilirubin &gt; 2.0 mg/dL Renal insufficiently (serum creatinine level &gt; 2.5 mg/dl or
        Creatinine clearance &lt; 30 mL/min calculated by Cockcroft-Gault estimation)

          -  Patients with active infections are ineligible.

          -  Patients who are HIV positive are ineligible.

          -  Patients with active leptomeningeal involvement are ineligible.

          -  Patients with a history of previous CSF tumor involvement without symptoms or signs
             are eligible provided the CSF is now free of disease on lumbar puncture, and MRI of
             the brain shows no tumor involvement.

          -  History of other malignancies within 3 years prior to study entry except for
             adequately treated carcinoma in situ of the cervix or basal or squamous cell skin
             cancer or breast, low grade, early stage localized prostate cancer treated surgically
             with curative intent (TNM stage of T1a or T1b),

          -  Patients with uncontrolled insulin-dependent diabetes mellitus or uncompensated major
             thyroid or adrenal dysfunction are ineligible.

          -  Patients with an ECOG performance status of &gt; 2 are ineligible.

          -  Malabsorption syndrome or uncontrolled gastrointestinal toxicities

          -  Clinically significant pleural effusion in the previous 12 months or current ascitis

          -  Clinically-significant coagulation or platelet function disorder

          -  Intolerance to bendamustine and/or lenalidomide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fortunato Morabito, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unità Operativa Complessa di Ematologia- Stabilimento Ospedaliero Annunziata - Azienda Ospedaliera di Cosenza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fortunato Morabito, MD</last_name>
    <phone>+390984681329</phone>
    <email>fortunato_morabito@tin.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fortunato Morabito, MD</last_name>
    <phone>+390984681539</phone>
    <email>fortunato_morabito@tin.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U. O. C. Ematologia - Azienda Ospedaliera Cosenza</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fortunato Morabito, MD</last_name>
      <phone>+390984681329</phone>
      <email>fortunato_morabito@tin.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001:2465-99.</citation>
  </reference>
  <reference>
    <citation>Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47. Erratum in: CA Cancer J Clin 2002 Mar-Apr;52(2):119. CA Cancer J Clin 2002 May-Jun;52(3):181-2.</citation>
    <PMID>11814064</PMID>
  </reference>
  <reference>
    <citation>Durie BG. The epidemiology of multiple myeloma. Semin Hematol. 2001 Apr;38(2 Suppl 3):1-5. Review.</citation>
    <PMID>11309701</PMID>
  </reference>
  <reference>
    <citation>Kishi Y, Oki Y, Machida U. Thalidomide in multiple myeloma. N Engl J Med. 2000 Mar 30;342(13):975; author reply 975-6.</citation>
    <PMID>10744492</PMID>
  </reference>
  <reference>
    <citation>Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42.</citation>
    <PMID>18032763</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.</citation>
    <PMID>18032762</PMID>
  </reference>
  <reference>
    <citation>Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol. 2007 Oct 1;25(28):4459-65. Epub 2007 Sep 4.</citation>
    <PMID>17785703</PMID>
  </reference>
  <reference>
    <citation>Anger G, Hesse P, Baufeld H. [Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride]. Dtsch Med Wochenschr. 1969 Nov 28;94(48):2495-500. Review. German.</citation>
    <PMID>4903552</PMID>
  </reference>
  <reference>
    <citation>Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. doi: 10.1158/1078-0432.CCR-07-1061.</citation>
    <PMID>18172283</PMID>
  </reference>
  <reference>
    <citation>Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12. Epub 2006 Jan 10.</citation>
    <PMID>16402269</PMID>
  </reference>
  <reference>
    <citation>Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D; East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008 Oct;143(2):191-200. doi: 10.1111/j.1365-2141.2008.07076.x. Epub 2008 Aug 24.</citation>
    <PMID>18752593</PMID>
  </reference>
  <reference>
    <citation>List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57.</citation>
    <PMID>15703420</PMID>
  </reference>
  <reference>
    <citation>List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65.</citation>
    <PMID>17021321</PMID>
  </reference>
  <reference>
    <citation>Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.</citation>
    <PMID>17893227</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Jacobus S, Callander N et al. Phase III trial of lenalidomide plus high- dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007.</citation>
  </reference>
  <reference>
    <citation>Rajkumar SV, Jacobus S, Callander N et al. A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.</citation>
  </reference>
  <reference>
    <citation>Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6.</citation>
    <PMID>17088571</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7.</citation>
    <PMID>8652811</PMID>
  </reference>
  <reference>
    <citation>Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84. doi: 10.1200/JCO.2008.20.8389. Epub 2009 Aug 3.</citation>
    <PMID>19652068</PMID>
  </reference>
  <reference>
    <citation>Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10;26(2):204-10. doi: 10.1200/JCO.2007.12.5070. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911.</citation>
    <PMID>18182663</PMID>
  </reference>
  <reference>
    <citation>Rummel MJ, von Gruenhagen U, Niederle N, et al: Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle-cell lymphomas: The first interim results of a randomized phase III study ofthe StiL (Study Group Indolent Lymphomas, Germany). Blood 110:120a, 2007 (abstr 385).</citation>
  </reference>
  <reference>
    <citation>Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2007 Dec;48(12):2345-51.</citation>
    <PMID>18067009</PMID>
  </reference>
  <reference>
    <citation>Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.</citation>
    <PMID>18094721</PMID>
  </reference>
  <reference>
    <citation>Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73. Epub 2006 Jul 20. Erratum in: Leukemia. 2007 May;21(5):1134. Leukemia. 2006 Dec;20(12):2220.</citation>
    <PMID>16855634</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2012</study_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Bendamustine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

